000117151 001__ 117151
000117151 005__ 20230914083414.0
000117151 0247_ $$2doi$$a10.1515/almed-2022-0006
000117151 0248_ $$2sideral$$a128654
000117151 037__ $$aART-2022-128654
000117151 041__ $$aeng
000117151 100__ $$aAlmenar Bonet, L.
000117151 245__ $$aSpecific test panels for patients with heart failure: implementation and use in the Spanish National Health System
000117151 260__ $$c2022
000117151 5060_ $$aAccess copy available to the general public$$fUnrestricted
000117151 5203_ $$aThe use of specific test panels (STP) for heart failure (HF) could help improve the management of this condition. The purpose of this study is to gain an insight into the level of implementation of STPs in the management of HF in Spain and gather the opinions of experts, with a special focus on parameters related to iron metabolism. The opinions of experts in HF were gathered in three stages STAGE 1 as follows: level of implementation of STPs (n=40). STAGE 2: advantages and disadvantages of STPs (n=12). STAGE 3: level of agreement with the composition of three specific STPs for HF: initial evaluation panel, monitoring panel, and de novo panel (n=16). In total, 62.5% of hospitals used STPs for the clinical management of HF, with no association found between the use of STPs and the level of health care (p=0.132) and location of the center (p=0.486) or the availability of a Heart Failure Unit in the center (p=0.737). According to experts, the use of STPs in clinical practice has more advantages than disadvantages (8 vs. 3), with a notable positive impact on diagnostics. Experts gave three motivations and found three limitations to the implementation of STPs. The composition of the three specific STPs for HF was viewed positively by experts. Although the experts interviewed advocate the use of diagnostic and monitoring STPs for HF, efforts are still necessary to achieve the standardization and homogenization of test panels for HF in Spanish hospitals.
000117151 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000117151 592__ $$a0.199$$b2022
000117151 593__ $$aMedical Laboratory Technology$$c2022$$dQ3
000117151 593__ $$aMedicine (miscellaneous)$$c2022$$dQ4
000117151 593__ $$aEducation$$c2022$$dQ4
000117151 594__ $$a0.7$$b2022
000117151 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000117151 700__ $$0(orcid)0000-0002-1662-7057$$aBlasco Peiró, M. T.$$uUniversidad de Zaragoza
000117151 700__ $$aLaiz Marro, B.
000117151 700__ $$aCamafort Babkowski, M.
000117151 700__ $$aBuño Soto, A.
000117151 700__ $$aCrespo-Leiro, M. G.
000117151 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000117151 773__ $$g3, 1 (2022), 65-70$$pAdv. lab. med$$tAdvances in laboratory medicine$$x2628-491X
000117151 8564_ $$s481122$$uhttps://zaguan.unizar.es/record/117151/files/texto_completo.pdf$$yVersión publicada
000117151 8564_ $$s2874096$$uhttps://zaguan.unizar.es/record/117151/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000117151 909CO $$ooai:zaguan.unizar.es:117151$$particulos$$pdriver
000117151 951__ $$a2023-09-13-11:55:14
000117151 980__ $$aARTICLE